Ovid Therapeutics Inc. (NASDAQ:OVID – Get Rating) – Investment analysts at William Blair reduced their Q2 2022 earnings per share (EPS) estimates for shares of Ovid Therapeutics in a report released on Tuesday, May 10th. William Blair analyst T. Lugo now forecasts that the company will post earnings of ($0.23) per share for the quarter, down from their prior forecast of ($0.22). William Blair also issued estimates for Ovid Therapeutics’ Q3 2022 earnings at ($0.24) EPS, Q4 2022 earnings at ($0.24) EPS, FY2022 earnings at ($0.93) EPS, Q1 2023 earnings at ($0.25) EPS, Q4 2023 earnings at ($0.27) EPS and FY2023 earnings at ($1.03) EPS.
Separately, Zacks Investment Research lowered Ovid Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, May 3rd.
Ovid Therapeutics (NASDAQ:OVID – Get Rating) last announced its earnings results on Tuesday, May 10th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.02).
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Geode Capital Management LLC increased its position in shares of Ovid Therapeutics by 22.3% during the 3rd quarter. Geode Capital Management LLC now owns 550,902 shares of the company’s stock worth $1,851,000 after purchasing an additional 100,378 shares during the last quarter. Capstone Investment Advisors LLC acquired a new position in Ovid Therapeutics in the 3rd quarter valued at about $55,000. Russell Investments Group Ltd. acquired a new position in Ovid Therapeutics in the 4th quarter valued at about $983,000. OLD Mission Capital LLC acquired a new position in Ovid Therapeutics in the 3rd quarter valued at about $317,000. Finally, Stonepine Capital Management LLC grew its position in Ovid Therapeutics by 62.6% in the 3rd quarter. Stonepine Capital Management LLC now owns 3,252,892 shares of the company’s stock valued at $10,930,000 after acquiring an additional 1,252,892 shares in the last quarter. Institutional investors and hedge funds own 48.29% of the company’s stock.
Ovid Therapeutics Company Profile (Get Rating)
Ovid Therapeutics Inc, a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies.
- Get a free copy of the StockNews.com research report on Ovid Therapeutics (OVID)
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
- Carvana Insiders Buy Shares But Maybe You Shouldn’t
- Dutch Bros Gets Scalded By Inflation
Receive News & Ratings for Ovid Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ovid Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.